The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Real-world outcomes of liso-cel therapy in R/R DLBCL
Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses a real-world analysis of outcomes for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel). In this patient population, who had a median of three prior lines of therapy and significant comorbidities, liso-cel was associated with favorable safety and efficacy outcomes that were comparable to those achieved in the TRANSCEND-NHL-001 trial (NCT02631044). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Genmab, ADC Therapeutics, Pharmacyclics, Novartis, BMS, Kite/Gilead, Nurix Therapeutics, Nektar Therapeutics, Takeda, Intellia Therapeutics, Sana Biotechnology, BeiGene, Janssen, CVS Caremark; Speakers Bureau: Kite/Gilead; Honoraria: Novartis; Research Funding: BMS, Kite/Gilead, Novartis, MorphoSys, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, Tessa Therapeutics.
